Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technology

Using Novel Digital Twins of Clinical Trial Participants, Unlearn is Accelerating Clinical Research to Help Bring New Treatments to Patients Sooner Unlearn, an AI company creating digital twins of clinical trial participants that enable smaller, faster studies, today announced a $50M Series C round led by Altimeter Capital, joined by returning investors Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital. This round of funding was secured to propel the company’s mission to advance AI to eliminate trial and error in medicine by investing in its people, data, engineering capabilities, and longer-term R&D initiatives. Founded in 2017 as an AI research company, Unlearn has always been at the forefront of developing innovative AI-based solutions for clinical trials. Now, seven years later, with over $130M raised, Unlearn’s technology addresses key clinical research challenges, such as long timelines, slow enrollment, and patients’ reluctance to participate over potentially receiving a placebo. Unlearn’s AI models generate an individual digital twin for every trial participant before they are randomized into the experimental or control arm. The participant’s digital twin forecasts their health outcomes under placebo, regardless of their actual assignment. Digital twins enable TwinRCTs, highly powered clinical trials with smaller control groups, allowing more patients to receive experimental treatment. TwinRCTs red...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT 8VC Altimeter Capital Charles Fisher DCVC DCVC Bio Epic Ventures Health IT Funding Health IT Fundings Health IT Investment Insight Partners Mubadala Capital Necessary Venture Capital Pauline Yang Source Type: blogs